未登录

P

Pravin T. P. Kaumaya

University System of Ohio

H指数:34

被引数:2,586

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer A Review

JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY

IF5.6

2023-02-014

PRE

A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)

IF6.3

2022-10-0517

OA

Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)

FRONTIERS IN ONCOLOGY

IF3.3

2022-05-1315

OAAI

IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations

BRITISH JOURNAL OF CANCER

IF6.8

2021-03-267

OAAI

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model

IF6.3

2020-10-0126

OAAI

B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine

FUTURE ONCOLOGY

IF2.6

2020-06-2131

OAAI

A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line

CANCER RESEARCH

IF16.6

2019-07-010

PRE

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2015-04-1519

OAAI

Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1

MOLECULAR PHARMACOLOGY

IF3

2015-02-0145

OAAI

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells

HER-3肽疫苗/模拟物: 与IGF-1R，HER-2和HER-1肽联合治疗可诱导对乳腺癌和胰腺癌细胞的协同抗肿瘤作用

IF6.3

2014-12-1725

OAAI

IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides

IF6.3

2014-12-1711

OAAI

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo

IF6.3

2014-10-2735

OAAI

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer

IF6.3

2014-10-2721

OAAI

Peptide Vaccines and Peptidomimetics of EGFR (HER-1) Ligand Binding Domain Inhibit Cancer Cell Growth In Vitro and In Vivo

JOURNAL OF IMMUNOLOGY

IF3.4

2013-07-0147

OA

Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy

FUTURE ONCOLOGY

IF2.6

2012-08-1546

OA

Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?

FUTURE ONCOLOGY

IF2.6

2011-07-067

PREAI

Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2011-04-0156

OAAI

Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF Signaling Pathways

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2011-04-0165

OAAI